Table 3. Associations between treatment costs and clinical value for indications supported by single-arm clinical trials in China.
| Variables | Model (1) Costs before negotiation |
Model (2) Costs after negotiation |
Model (3) Costs before and after negotiation |
|||
|---|---|---|---|---|---|---|
| Coefficient (95% CI) | P value | Coefficient (95% CI) | P value | Coefficient (95% CI) | P value | |
| ORR | 0.597 (0.163, 1.030) | 0.009 | 0.688 (0.179, 1.197) | 0.010 | 0.596 (0.140, 1.051) | 0.011 |
| Negotiation (ref = Before negotiation) | ||||||
| After negotiation | −0.495 (−0.899, −0.090) | 0.018 | ||||
| Negotiation × ORR (ref = Before negotiation × ORR) | ||||||
| After negotiation × ORR | 0.092 (−0.552, 0.735) | 0.776 | ||||
We log-transformed treatment costs for these regression analyses. CI, confidence interval; ORR, overall response rate. Negotiation × ORR refers to the interaction term involving negotiation status and ORR.